Ligand Pharmaceuticals Inc (LGND)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $5.65B
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Latest financial period: June 30, 2026
Filed with the SEC: August 7, 2026
Estimated earnings date: November 5, 2026
Profit #728 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 51.6% | 36.9% | 51.6% | 40.1% |
Growth #36 of 1484 companies
Payout #1117 of 1484 companies
Safety #734 of 1484 companies
Price #995 of 1484 companies
